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In this issue of Critical Care, Karlsson and colleagues [1] 
publish the results of a thorough prospective obser-
vational study of the predictive value of procalcitonin 
(PCT) in 24 intensive care units (ICUs) in Finland at ICU 
admission and 72 hours later. Th   e success story of PCT in 
the ICU is based on this biomarker’s relative speciﬁ  city 
for bacterial infection and its easy and rapid measure-
ment in serum. Although PCT is used in many ICUs 
every day, the question of whether this biomarker has 
real usefulness is worth investigating.
PCT for use in the critically ill has four main indica-
tions: diagnosis of severe bacterial infection, evalu  ation 
of sepsis severity, assessment of the appropriateness of 
therapy (antibiotics or surgery/drainage), and tailoring of 
antibiotic prescription (indication and duration) while 
keeping in mind that bacterial multidrug resistance has 
prompted the development of strategies to reduce anti-
biotic consumption. We want many things from bio-
markers, perhaps too much! For example, we are still 
waiting for the ideal biomarker that could help us predict 
the individual outcomes of patients with severe sepsis 
and septic shock. Early detection of patients at high vital 
risk is of utmost importance.
Th  e report by Karlsson and colleagues provides some 
interesting results but also some disappointing ones. 
First, the absolute serum PCT level had no direct impact 
on prognosis. PCT concentrations did not diﬀ  er between 
survivors and nonsurvivors at either time point. Does 
that mean biomarkers are not useful tools to predict 
outcome? In a recent study of patients with community-
acquired pneumonia (most of whom were not admitted 
to the ICU), PCT was higher in patients who died, but 
proadrenomedullin performed the best at predicting 
short- and long-term survival [2]. However, it is hard to 
imagine that a single biomarker could be a reliable 
predictor of outcome of patients with severe sepsis. 
Perhaps the combination of clinical data and several 
biomarkers would perform better.
Second, much more relevant than a single PCT level 
are serial PCT determinations after the therapeutic inter-
vention. According to the authors, in-hospital mortality 
was lower for patients whose PCT concentrations 
diminished more than 50% by 72 hours compared with 
those with a decline of less than 50%; however, PCT 
decrease of more than 50% was not independently 
associated with outcome. Th   ese results mean that future 
studies should focus on PCT kinetics. Because daily 
measurement would raise costs, future research should 
use mathematical models to try to ﬁ  nd the best predictive 
rule, requiring fewer PCT measurements.
Th  ird, 15% of the patients with severe sepsis had low 
PCT levels. Indeed, it is well known that, in some 
Abstract
In infl  ammatory states, particularly in response to 
infectious stimuli, local procalcitonin (PCT) production 
rises, and because these tissues cannot further process 
PCT into calcitonin, serum levels increase. In the 
critical care setting, PCT should be considered a useful 
tool to help physicians in some specifi  c, although 
frequent, situations. Serial measurements of PCT levels 
may indicate the eff  ectiveness of medical decisions 
such as the appropriateness of antibiotic therapy, the 
detection of new infections, and the exclusion of a 
diagnosis of sepsis. PCT-guided algorithms may also 
help to decrease the duration of antimicrobial therapy. 
However, the role of PCT as a prognostic marker in 
critically ill patients is controversial. In a study by 
Karlsson and colleagues, PCT concentrations did not 
diff  er between hospital survivors and nonsurvivors, 
but the outcome was better in patients whose PCT 
concentrations decreased more than 50%. The study 
of PCT kinetics thus could off  er an individual risk 
assessment in patients with severe sepsis.
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© 2010 BioMed Central Ltdsituations (for example, locally restricted inﬂ  ammatory 
reactions), PCT levels may stay within the normal range. 
When antimicrobials are initially withheld, clinical re-
evaluation and repeated PCT measurements 6 to 
12 hours later are recommended to detect a late peak of 
PCT level and to ensure that antibiotics are provided to 
patients who have true bacterial infections [3]. Karlsson 
and colleagues found that the median PCT concen  tra  tions 
on day 0 were 42% lower in patients with noso  comial 
infec  tions (44% had pneumonia) in comparison with those 
with community-acquired infections. Th  is obser  vation is 
important as it suggests that PCT could be more useful for 
detection of infection and monitoring of therapeutic 
interventions in community-acquired infec  tions. Th  e 
use  fulness of PCT as a tool to diagnose ventilator-
associated pneumonia (VAP) yielded conﬂ  icting results. 
In one study, the areas under the receiver operating 
charac  teristic curves were 0.87 for PCT and 0.96 when 
PCT was combined with the clinical pulmonary infection 
score (CPIS) [4]. Another study found that including 
PCT in the CPIS did not increase its accuracy for the 
diagnosis of VAP [5], whereas increased PCT improved 
speciﬁ  city but not sensitivity [6].
Finally, although high PCT levels may detect a sub-
group of patients with positive blood cultures [7], the 
clinical relevance of this ﬁ  nding is uncertain and would 
not eliminate the need for drawing blood for cultures, 
which could be the only way to identify the 
micro organism.
Clearly, PCT is the most useful biomarker of bacterial 
infection available for routine use in the ICU. Th  e  study 
by Karlsson and colleagues has the merit of summarizing 
its advantages and limitations as a tool to diagnose severe 
sepsis and predict outcome.
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